Subscribe to The BMJ’s news feed.
Click on “Follow” and decide if you want to get news from The BMJ via RSS, as email newsletter, via mobile or on your personal news page.
Subscription to The BMJ comes without risk as you can unsubscribe instantly at any time.
You can also filter the feed to your needs via topics and keywords so that you only receive the news from The BMJ which you are really interested in. Click on the blue “Filter” button below to get started.
Website title: The BMJ: Leading Medical Research, News, Education, Opinion
Is this your feed? Claim it!
Dear Editor
Paulo reports that only 21% of NHS hospital trusts use fully electronic systems for clinical notes.[1] From the perspective of clinicians working in hospitals where electronic records have already largely replaced paper, digitisation alone does not necessarily reduce documentation.
In our daily practice, the same clinical hist...
Dear Editor
I was really pleased to read the article by Anja Hellman and colleagues summarising the negative impact of physical punishment of children and calling for a change in the law. The response by Santhanam Sundar is concerning, however, as it appears to say that although smacking is bad, other forms of punishment are needed to ensure chi...
Dear Editor
I would like to thank the authors for this carefully designed target-trial emulation, which helps address a gap left by SURPASS-CVOT [1]. The new-user, active-comparator design, propensity-score overlap weighting, and benchmarking against SURPASS-CVOT via the RCT-DUPLICATE framework reflect a rigorous approach that adds meaningfully ...
Dear Editor,
We read with interest Shenoy and colleagues’ multicentre emulated target trial, which found that rasburicase administered within 12 hours of tumour lysis syndrome (TLS) onset was associated with a lower risk of kidney replacement therapy or death than delayed or no treatment (32.7% v 42.0%; adjusted odds ratio 0.67) (1). The clinica...
Dear Editor
Krüger and colleagues provide a careful, preregistered estimate of tirzepatide's cardiovascular effectiveness in routine care. Their results raise a narrower question: should all-cause mortality strengthen the headline MACE estimate?[1]
MACE comprised myocardial infarction, stroke, and all-cause death. The weighted one-year ri...